Related Experiment Video
Updated: May 2, 2026
05:46
Introduction of Intracapsular Rotary-cut Procedures IRCP: A Modified Hysteromyomectomy Procedures Facilitating Fertility Preservation
Published on: January 17, 2019
9.3K
Implementation and early clinical results utilizing Cs-131 permanent interstitial implants for gynecologic
Charles Eric Wooten1, Marcus Randall1, Jason Edwards1
1Department of Radiation Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY, USA.
Gynecologic Oncology
|February 22, 2014
Summary
Cesium-131 (Cs-131) permanent interstitial brachytherapy shows promising early results for gynecological cancers, offering good local control with minimal side effects. This treatment is well-tolerated and minimizes radiation exposure for medical staff.
Area of Science:
- Oncology
- Medical Physics
- Radiotherapy
Background:
- Permanent interstitial brachytherapy is an effective treatment for gynecological malignancies but is underutilized.
- Cesium-131 (Cs-131) is a new permanent isotope for brachytherapy.
Purpose of the Study:
- To present early clinical results of permanent interstitial brachytherapy using Cs-131.
- To evaluate the safety and efficacy of Cs-131 in treating gynecological cancers.
Main Methods:
- Retrospective review of patients treated with Cs-131 permanent interstitial radiation from July 2011 to June 2013.
- Dose prescription and calculation followed Paterson-Parker planar implant rules, with adjustments for Cs-131's relative biological effectiveness (RBE).
Main Results:
- 17 Cs-131 implants were performed in 14 patients.
- Actuarial local control rate was 84.4% after a median follow-up of 12 months.
- Low rates of grade 1-3 reactions were observed, with no severe side effects like fistula formation.
Conclusions:
- Permanent interstitial brachytherapy with Cs-131 is well-tolerated and demonstrates favorable early outcomes.
- Cs-131 offers benefits such as reduced radiation exposure for healthcare professionals.
- Cs-131 should be considered for appropriately selected patients with gynecological malignancies.
